Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- Antiviral activities of antibodies in vitro
- Anti-viral activities of antibodies overview
- Neutralization
- Neutralization assay
- HIV-1 pseudovirus neutralization assay
- Neutralization curves JRCSF
- Neutralization curves - 01US056
- How do antibodies neutralize viruses?
- Early history of antibody neutralizaion
- NAbs to HIV are directed to Env spikes
- Neutralization and affinity to envelope trimers
- HIV makes contact with a target cell
- Antibody interferes with viral attachment
- Must antibodies bind to the virus to neutralize?
- Flag Tag introduction to the V4 loop
- HIV-1 YU2 glycoprotein ineffectivity
- Neutralizing HIV-1 YU2 variants by IgG1b12 Ab
- Neutralizing HIV-1 YU2 variants by -FLAG Ab
- Inhibition of infection by antibody binding to HIV-1
- Example: neutralizing Ab against influenza
- Correlation between number of Abs and virion size
- Rhinovirus neutralization
- Kinetic effects in Ab neutralization
- Component mediated lysis and phagocytosis
- Further activities against free virus
- Antibody activities against infection
- Activities against infected cells
- Antibody-mediated enhancement of infection
- Infection enhancement for HIV
- Antiviral activities of antibodies in vivo
- Two scenarios for antibody activity in vivo
- Protection
- Human HIV infection in SCID mice
- Neutralization and protection in huPBL-SCID mice
- IgG1 b12 antibody protects macaques
- Neutralization/protection correlation for mAb b12
- Requirements for passive antibody protection
- Antibody protection against Ebola virus
- Location for Ebola virus study
- Documentation in ASM News
- Human mAb KZ52 neutralizes Ebola
- Protection ability of KZ52
- Ebola virus challenge in the macaque model
- Neutralizing antibody prophylaxis in macaques
- Effective use of monoclonal antibodies
- Evidence for other mechansims of protection
- Protection ability of non-neutralizing Abs
- Antibodies in vaccine protection
- Therapy
- Investigating Ab efficacy in therpay
- Treating HIV-infected mice with a 3-Ab cocktail
- Escape from each of the mAbs
- Interplay between Ab levels and viral variants
- Viral strategies for avoiding antibody responses
- Envelope structural features
- Conclusions (1)
- Conclusions (2)
Topics Covered
- Anti-viral activities of antibody in vitro
- Neutralization
- Mechanisms of neutralization
- Other activities against free viruses
- Activities against infected cells
- Antibody mediated enhancement
- Anti-viral activities of antibodies in vivo
- Protection
- Antibodies in therapy of viral infection
- Viral strategies for avoiding antibody responses
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Burton, D. (2007, October 1). Antibodies as anti-virals [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 8, 2024, from https://doi.org/10.69645/XBCH9533.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Dennis Burton has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.